Supernus, Inc. Completes Merger; Indivior Holders Own 56.5%
Supernus, Inc. completed its merger with Indivior, with former Indivior stockholders owning 56.5% of the combined company. The deal enhances cash flow, scale, and pipeline, with the new entity trading as SUPN on Nasdaq from November 3, 2026. Indivior holders receive a $1B cash dividend, funded partly by a $650M term loan.
How this was made
The 30-second read
Why it matters
The merger introduces a larger cash flow profile, a $1B dividend, and $650M term loan, prompting market pricing of the new entity.
Market read
First report of the merger completion and new ticker launch, a material M&A event for biotech investors.
What to watch
Potential regulatory scrutiny of the merger and the ability to realize projected synergies.
Background
Supernus completed its merger with Indivior, forming a diversified CNS biopharma with a new ticker SUPN.
Ticker impact
Merger completed; combined company will trade under SUPN on Nov 3, 2026, with Indivior holders owning 56.5% and a $1B cash dividend.
likely pressure as the market prices in the new ticker and dividend, with upside if integration proceeds smoothly
First‑day trading of SUPN will reflect the merger premium, cash dividend and leverage from the $650M term loan.
Market effects
Creates a larger CNS biopharma player, potentially reshaping competitive dynamics in the CNS drug market.
Adds a more sizable biotech presence on the Nasdaq, modestly boosting US biotech sector weight.
Limited to CNS therapeutic space; no broad macro impact.
Counterpoint
Integration risks and added debt could weigh on the combined company's valuation despite the cash dividend.
Key entities
- CompanySupernus, Inc.
Merged entity now trading as SUPN.
- CompanyIndivior
Former shareholders own 56.5% of the combined company.
